SNDL INC (SNDL) Stock Fundamental Analysis
USA - NASDAQ:SNDL - CA83307B1013 - Common Stock
2.58 USD
+0.05 (+1.98%)
2.5799 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to SNDL. SNDL was compared to 196 industry peers in the Pharmaceuticals industry. While SNDL has a great health rating, there are worries on its profitability. SNDL has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
SNDL had negative earnings in the past year.
SNDL had a positive operating cash flow in the past year.
SNDL had negative earnings in each of the past 5 years.
In the past 5 years SNDL reported 4 times negative operating cash flow.
1.2 Ratios
SNDL's Return On Assets of -7.60% is fine compared to the rest of the industry. SNDL outperforms 70.05% of its industry peers.
SNDL has a Return On Equity of -9.03%. This is in the better half of the industry: SNDL outperforms 75.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.6% | ||
| ROE | -9.03% | ||
| ROIC | N/A |
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SNDL's Gross Margin of 27.11% is in line compared to the rest of the industry. SNDL outperforms 54.31% of its industry peers.
In the last couple of years the Gross Margin of SNDL has remained more or less at the same level.
SNDL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 27.11% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
2. Health
2.1 Basic Checks
SNDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNDL has about the same amount of shares outstanding.
SNDL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SNDL has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.31 indicates that SNDL is not a great score, but indicates only limited risk for bankruptcy at the moment.
SNDL has a Altman-Z score of 2.31. This is in the better half of the industry: SNDL outperforms 68.02% of its industry peers.
The Debt to FCF ratio of SNDL is 3.03, which is a good value as it means it would take SNDL, 3.03 years of fcf income to pay off all of its debts.
SNDL has a better Debt to FCF ratio (3.03) than 89.85% of its industry peers.
SNDL has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of SNDL (0.11) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 2.31 |
ROIC/WACCN/A
WACC9.03%
2.3 Liquidity
SNDL has a Current Ratio of 5.03. This indicates that SNDL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SNDL (5.03) is better than 69.54% of its industry peers.
A Quick Ratio of 3.36 indicates that SNDL has no problem at all paying its short term obligations.
SNDL's Quick ratio of 3.36 is fine compared to the rest of the industry. SNDL outperforms 60.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.03 | ||
| Quick Ratio | 3.36 |
3. Growth
3.1 Past
SNDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.14%, which is quite good.
The Revenue has been growing slightly by 3.54% in the past year.
Measured over the past years, SNDL shows a very strong growth in Revenue. The Revenue has been growing by 70.65% on average per year.
EPS 1Y (TTM)13.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150.23%
Revenue 1Y (TTM)3.54%
Revenue growth 3Y154.1%
Revenue growth 5Y70.65%
Sales Q2Q%7.3%
3.2 Future
The Earnings Per Share is expected to grow by 42.75% on average over the next years. This is a very strong growth
SNDL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.35% yearly.
EPS Next Y81.82%
EPS Next 2Y43.55%
EPS Next 3Y33.21%
EPS Next 5Y42.75%
Revenue Next Year4.09%
Revenue Next 2Y4.1%
Revenue Next 3Y4.71%
Revenue Next 5Y5.35%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SNDL. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 353.24, SNDL can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, SNDL is valued a bit cheaper than the industry average as 66.50% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.32, SNDL is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 353.24 |
4.2 Price Multiples
SNDL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SNDL is cheaper than 80.71% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SNDL is valued cheaper than 84.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.65 | ||
| EV/EBITDA | 19.16 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SNDL does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as SNDL's earnings are expected to grow with 33.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.55%
EPS Next 3Y33.21%
5. Dividend
5.1 Amount
No dividends for SNDL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.58
+0.05 (+1.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners16.56%
Inst Owner Change0%
Ins Owners4.32%
Ins Owner ChangeN/A
Market Cap663.96M
Analysts82.5
Price Target4.15 (60.85%)
Short Float %1.05%
Short Ratio0.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)91.42%
Min EPS beat(2)63.24%
Max EPS beat(2)119.61%
EPS beat(4)3
Avg EPS beat(4)122.67%
Min EPS beat(4)-37.25%
Max EPS beat(4)345.1%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.36%
Min Revenue beat(2)-6.38%
Max Revenue beat(2)3.66%
Revenue beat(4)2
Avg Revenue beat(4)-0.24%
Min Revenue beat(4)-6.38%
Max Revenue beat(4)3.66%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-41.94%
PT rev (3m)16.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-20%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)0.57%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 353.24 | ||
| P/S | 0.98 | ||
| P/FCF | 18.65 | ||
| P/OCF | 15.25 | ||
| P/B | 0.85 | ||
| P/tB | 1.03 | ||
| EV/EBITDA | 19.16 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.01
Fwd EY0.28%
FCF(TTM)0.14
FCFY5.36%
OCF(TTM)0.17
OCFY6.56%
SpS2.63
BVpS3.03
TBVpS2.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.6% | ||
| ROE | -9.03% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 27.11% | ||
| FCFM | 5.27% |
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
F-Score7
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.6 | ||
| Cap/Depr | 19.75% | ||
| Cap/Sales | 1.17% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 135.06% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.03 | ||
| Quick Ratio | 3.36 | ||
| Altman-Z | 2.31 |
F-Score7
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)18.2%
Cap/Depr(5y)23.85%
Cap/Sales(3y)1.2%
Cap/Sales(5y)3.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150.23%
EPS Next Y81.82%
EPS Next 2Y43.55%
EPS Next 3Y33.21%
EPS Next 5Y42.75%
Revenue 1Y (TTM)3.54%
Revenue growth 3Y154.1%
Revenue growth 5Y70.65%
Sales Q2Q%7.3%
Revenue Next Year4.09%
Revenue Next 2Y4.1%
Revenue Next 3Y4.71%
Revenue Next 5Y5.35%
EBIT growth 1Y76.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year710.87%
EBIT Next 3Y150.28%
EBIT Next 5Y93%
FCF growth 1Y268.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y397.24%
OCF growth 3YN/A
OCF growth 5YN/A